Changes

==== Prognosis considering present developments in medicine ====

==== Prognosis considering present developments in medicine ====

The disease with involvement of single dosha and new (diagnosed within one year) is curable. The disease with involvement of more than one dosha and chronic (more than one year) is palliable with medicines and appropriate therapies.   

The disease with involvement of single ''dosha'' and new (diagnosed within one year) is curable. The disease with involvement of more than one ''dosha'' and chronic (more than one year) is palliable with medicines and appropriate therapies.   

Management of diseases (Treatment protocols)  

 

Principles of management: 1. Basti 2. Snehana 3. Raktamokshana

==== Management of diseases (Treatment protocols) ====

 

Basti (therapeutic enema): Basti with herbs of ruksha (dry) property or mrudu (mild) property are used to treat both uttana (superficial) and gambhira (deep) types of vatarakta.  

===== Principles of management =====

Raktamokshana (bloodletting):  Bloodletting is prescribed as per dosha dominance in vatarakta patients. This gives better results to remove obstruction and reduce vitiation of blood.   

 

#''Basti'' (therapeutic enema): ''Basti'' with herbs of ''ruksha'' (dry) property or ''mridu'' (mild) property are used to treat both ''uttana'' (superficial) and ''gambhira'' (deep) types of ''vatarakta''.  

#''Raktamokshana'' (bloodletting):  Bloodletting is prescribed as per ''dosha'' dominance in ''vatarakta'' patients. This gives better results to remove obstruction and reduce vitiation of blood.   

 

Main drugs: 1. Guduchi 2. Kokilaksha 3. Suranjan  

Main drugs: 1. Guduchi 2. Kokilaksha 3. Suranjan  

Type Name Dose Time Anupana

Type Name Dose Time Anupana

Kaphaja Guda-bhallataka-haritaki vati 1 -3 grams Before meals two times Milk or lukewarm water

Kaphaja Guda-bhallataka-haritaki vati 1 -3 grams Before meals two times Milk or lukewarm water

Evidence based clinical practices:

===== Evidence based clinical practices =====

A study reviewing anti-rheumatic formulations showed that 247 formulations are enlisted in ayurveda texts. rasnasaptak kwath, ajmodadi choorna, vatavidhvanasan rasa, vatari rasa, sinhanad guggulu, yogaraj guggulu,  khandashunthyavaleha, amrit bhallatak, guggulu panchatikta ghrita, vishagarbha taila are common formulations used to treat rheumatic conditions. Yogaraja guggulu is used in 50% prescriptions for rheumatic cases.  

A research on vatarakta concluded that the notion of margavarana (obstruction in pathway) can be correlated to the pathology of atherosclerosis, and the state of uttana vatarakta to that of peripheral arterial disease. Identical therapeutic efficacy of kaishora guggulu and amrita guggulu was observed in thirty patients of uttana vatarakta.   

A study reviewing anti-rheumatic formulations showed that 247 formulations are enlisted in Ayurveda texts. ''rasnasaptaka kwath'', ''ajmodadi choorna, vatavidhvanasana rasa, vatari rasa, sinhanad guggulu, yogaraj guggulu,  khandashunthyavaleha, amrit bhallatak, guggulu panchatikta ghrita, vishagarbha taila'' are common formulations used to treat rheumatic conditions. ''Yogaraja guggulu'' is used in 50% prescriptions for rheumatic cases.  

Another study was carried out to evaluate the antioxidant effect of five kashayams (kwaths - decoctions) manjishtadi kashayam (MK), rasna erandadi kashayam (REK),  sahacharadhi kashayam (SK), maharasnadi (or rasna dwiguna bhagam) kashayam (MRK) and dhanwantharam kashayam (DK) used in the management of diseases manifested due to vitiation of vata and vatarakta (mostly diseases of connective tissues, bones, joints and nervous system). It concluded that the total phenolic content and the antioxidant property of the products justify the protective and corrective effects produced by the products in vata and vatarakta disorders. The phenolic content is highest in MK, followed by DK. The phenolic content of MRK, SK and REK are comparable.  This shows the formulations act by scavenging the free radicals in rheumatic diseases.  

 

Potential areas /scope for further research

A research on ''vatarakta'' concluded that the notion of ''margavarana'' (obstruction in pathway) can be correlated to the pathology of atherosclerosis, and the state of ''uttana vatarakta'' to that of peripheral arterial disease. Identical therapeutic efficacy of ''kaishora guggulu'' and ''amrita guggulu'' was observed in thirty patients of ''uttana vatarakta''.   

Study to evaluate the efficacy of basti and bloodletting therapies in the management of vatarakta is needed. Further studies to evaluate the effect of ayurvedic formulations in management of vatarakta are needed.  

 

Another study was carried out to evaluate the antioxidant effect of five ''kashayams'' (''kwaths'' - decoctions) ''manjishtadi kashayam'' (MK), ''rasna erandadi kashayam'' (REK),  ''sahacharadhi kashayam'' (SK), ''maharasnadi'' (or ''rasna dwiguna bhagam'') ''kashayam'' (MRK) and ''dhanwantharam kashayam'' (DK) used in the management of diseases manifested due to vitiation of ''vata'' and ''vatarakta'' (mostly diseases of connective tissues, bones, joints and nervous system). It concluded that the total phenolic content and the antioxidant property of the products justify the protective and corrective effects produced by the products in ''vata'' and ''vatarakta'' disorders. The phenolic content is highest in MK, followed by DK. The phenolic content of MRK, SK and REK are comparable.  This shows the formulations act by scavenging the free radicals in rheumatic diseases.  

 

==== Potential areas /scope for further research ====

 

Study to evaluate the efficacy of ''basti'' and bloodletting therapies in the management of ''vatarakta'' is needed. Further studies to evaluate the effect of Ayurvedic formulations in management of ''vatarakta'' are needed.

References:

References: